Classical CRISPR systems use molecular scissors to snip through DNA ... "Autoimmune diseases — type 1 diabetes, multiple ...

CRISPR Therapeutics AG CRSP shares soared 8.7% in the last trading session to close at $76.78. The move was backed by solid volume with far more shares changing hands than in a normal session. This ...

In the latest close session, CRISPR Therapeutics AG (CRSP) was down 6.54% at $68.29. The stock trailed the S&P 500, which registered a daily gain of 1.56%. On the other hand, the Dow registered a gain ...

Crispr Therapeutics maintains leadership in gene editing, with shares up 75% YTD and renewed investor interest after positive CTX-310 data. CRSP's in-vivo therapy shows promising early results, ...

NEW YORK, NY – Two prominent biotechnology companies, Vertex Pharmaceuticals and CRISPR Therapeutics, both led by Indian American CEOs, have been named to TIME’s 2025 list of the 100 Most Influential ...

Lozano is a rare disease mom, neuroscience Ph.D. candidate at UC Davis, and board member for the PURA Syndrome Foundation. In May, a historic moment in science and medicine was captured in a single ...

There's good news for Chron's disease sufferers according to an NHS GP, who has talked about a new treatment for the condition that has been approved in the UK. Crohn's disease is a long-term ...

The rings of DNA inside mitochondria are inaccessible to these techniques, which means that precise edits to mitochondrial DNA (mtDNA) remain frustratingly out of reach. “Mitochondria missed the ...

Please provide your email address to receive an email when new articles are posted on . A CRISPR-Cas9-based therapy reduced transthyretin levels in patients with hereditary amyloidosis and ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min A small S.F. biotech with ties ...